Cargando…

High-throughput behavioral screen in C. elegans reveals Parkinson’s disease drug candidates

We recently linked branched-chain amino acid transferase 1 (BCAT1) dysfunction with the movement disorder Parkinson’s disease (PD), and found that RNAi-mediated knockdown of neuronal bcat-1 in C. elegans causes abnormal spasm-like ‘curling’ behavior with age. Here we report the development of a mach...

Descripción completa

Detalles Bibliográficos
Autores principales: Sohrabi, Salman, Mor, Danielle E., Kaletsky, Rachel, Keyes, William, Murphy, Coleen T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884385/
https://www.ncbi.nlm.nih.gov/pubmed/33589689
http://dx.doi.org/10.1038/s42003-021-01731-z
_version_ 1783651403724488704
author Sohrabi, Salman
Mor, Danielle E.
Kaletsky, Rachel
Keyes, William
Murphy, Coleen T.
author_facet Sohrabi, Salman
Mor, Danielle E.
Kaletsky, Rachel
Keyes, William
Murphy, Coleen T.
author_sort Sohrabi, Salman
collection PubMed
description We recently linked branched-chain amino acid transferase 1 (BCAT1) dysfunction with the movement disorder Parkinson’s disease (PD), and found that RNAi-mediated knockdown of neuronal bcat-1 in C. elegans causes abnormal spasm-like ‘curling’ behavior with age. Here we report the development of a machine learning-based workflow and its application to the discovery of potentially new therapeutics for PD. In addition to simplifying quantification and maintaining a low data overhead, our simple segment-train-quantify platform enables fully automated scoring of image stills upon training of a convolutional neural network. We have trained a highly reliable neural network for the detection and classification of worm postures in order to carry out high-throughput curling analysis without the need for user intervention or post-inspection. In a proof-of-concept screen of 50 FDA-approved drugs, enasidenib, ethosuximide, metformin, and nitisinone were identified as candidates for potential late-in-life intervention in PD. These findings point to the utility of our high-throughput platform for automated scoring of worm postures and in particular, the discovery of potential candidate treatments for PD.
format Online
Article
Text
id pubmed-7884385
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78843852021-02-25 High-throughput behavioral screen in C. elegans reveals Parkinson’s disease drug candidates Sohrabi, Salman Mor, Danielle E. Kaletsky, Rachel Keyes, William Murphy, Coleen T. Commun Biol Article We recently linked branched-chain amino acid transferase 1 (BCAT1) dysfunction with the movement disorder Parkinson’s disease (PD), and found that RNAi-mediated knockdown of neuronal bcat-1 in C. elegans causes abnormal spasm-like ‘curling’ behavior with age. Here we report the development of a machine learning-based workflow and its application to the discovery of potentially new therapeutics for PD. In addition to simplifying quantification and maintaining a low data overhead, our simple segment-train-quantify platform enables fully automated scoring of image stills upon training of a convolutional neural network. We have trained a highly reliable neural network for the detection and classification of worm postures in order to carry out high-throughput curling analysis without the need for user intervention or post-inspection. In a proof-of-concept screen of 50 FDA-approved drugs, enasidenib, ethosuximide, metformin, and nitisinone were identified as candidates for potential late-in-life intervention in PD. These findings point to the utility of our high-throughput platform for automated scoring of worm postures and in particular, the discovery of potential candidate treatments for PD. Nature Publishing Group UK 2021-02-15 /pmc/articles/PMC7884385/ /pubmed/33589689 http://dx.doi.org/10.1038/s42003-021-01731-z Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Sohrabi, Salman
Mor, Danielle E.
Kaletsky, Rachel
Keyes, William
Murphy, Coleen T.
High-throughput behavioral screen in C. elegans reveals Parkinson’s disease drug candidates
title High-throughput behavioral screen in C. elegans reveals Parkinson’s disease drug candidates
title_full High-throughput behavioral screen in C. elegans reveals Parkinson’s disease drug candidates
title_fullStr High-throughput behavioral screen in C. elegans reveals Parkinson’s disease drug candidates
title_full_unstemmed High-throughput behavioral screen in C. elegans reveals Parkinson’s disease drug candidates
title_short High-throughput behavioral screen in C. elegans reveals Parkinson’s disease drug candidates
title_sort high-throughput behavioral screen in c. elegans reveals parkinson’s disease drug candidates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884385/
https://www.ncbi.nlm.nih.gov/pubmed/33589689
http://dx.doi.org/10.1038/s42003-021-01731-z
work_keys_str_mv AT sohrabisalman highthroughputbehavioralscreenincelegansrevealsparkinsonsdiseasedrugcandidates
AT mordaniellee highthroughputbehavioralscreenincelegansrevealsparkinsonsdiseasedrugcandidates
AT kaletskyrachel highthroughputbehavioralscreenincelegansrevealsparkinsonsdiseasedrugcandidates
AT keyeswilliam highthroughputbehavioralscreenincelegansrevealsparkinsonsdiseasedrugcandidates
AT murphycoleent highthroughputbehavioralscreenincelegansrevealsparkinsonsdiseasedrugcandidates